In AZURE, ER-positive premenopausal women [the same population as in the ABCSG
XII trial] are showing no benefit--in fact, there's almost a disadvantage with zoledronic acid--and that's clearly different from ABCSG
12," said Dr.
is currently recruiting up to 30 percent of all Austrian breast cancer patients into their clinical trial program.
Nearly 800 patients who were randomized to the tamoxifen-only arm of ABCSG
8 elected to switch to anastrozole following widely publicized reports at the 2004 San Antonio symposium that 5 years of an aromatase inhibitor resulted in significantly better recurrence-free survival than did 5 years of tamoxifen.
is currently recruiting up to 40 percent of all Austrian breast cancer patients into their clinical trial program.
Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG
trial 8 and ARNO 95 trial.
Switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-responsive early breast cancer: a meta-analysis of the ARNO 95 trial, ABCSG
Trial 8, and the ITA trial.
Benefits of switching postmenopausal women with hormone-sensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results from 3123 women enrolled in the ABCSG
Trial 8 and the ARNO 95 Trial.
In a separate presentation, data from a meta-analysis combining the ABCSG
Trial 8 data with two additional studies in which patients were switched from tamoxifen to ARIMIDEX (see general session 3, program 19, W.
and ARNO trials were designed to assess, in patients who had already started a course of adjuvant treatment with tamoxifen, whether changing therapy to anastrozole after 2 years is more effective than continuing treatment with tamoxifen.
In certain patient risk groups, ABCSG
is currently recruiting up to 40% of all Austrian breast cancer patients in clinical trials.
The Astra Zeneca trials, ARNO 95 and ABCSG
8, are being conducted to assess whether switching to anastrozole after two years of tamoxifen treatment is more effective than continuing tamoxifen treatment for the remaining three years of adjuvant therapy.
Data was also reported today on the combined results from ABCSG
Trial 8 & ARNO 95 trials, (3,123 women) which studied postmenopausal women with hormone receptor-positive early breast cancer who were switched to ARIMIDEX after 2 years of tamoxifen treatment.